AstraZeneca will buy all outstanding equity of EsoBiotec for on a cash and debt-free basis, which includes an initial payment of $425 million on deal closing, and up to $575 million in contingent ...

Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “We are excited about the acquisition of EsoBiotec and the opportunity to rapidly advance their promising ...

AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging field of treatments that can reprogramme immune cells inside patients ...

EsoBiotec will become a wholly owned subsidiary of AstraZeneca, with operations in Belgium. New platform allows quicker cancer treatment delivery. In a market dominated by tariff tensions ...

British drug major AstraZeneca said on Monday it has entered into a definitive agreement to acquire EsoBiotec, a Belgian biotech company, for up to $1 billion on a cash and debt-free basis.

GAITHERSBURG, Md. (DC News Now) — AstraZeneca is making a major push into cell therapy with the acquisition of EsoBiotec, a company that has developed a groundbreaking approach to fighting cancer.

executive vice president of Oncology Haematology R&D at AstraZeneca, the deal could help expand the scope of cell therapy and make these treatments availabe globally. EsoBiotec CEO Jean-Pierre ...